---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-012521"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2022-09-14T23:59:59+00:00"
generated_at: "2026-06-23T09:38:56.882998+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv Q3 revenue $4.8M, net income $0.3M down $2M YoY on SBA loan forgiveness

## Summary
- Revenue for Q3 ended July 31, 2022: $4.8M, down $0.2M YoY; 9-month revenue $14.8M, up $0.2M.
- Net income Q3: $0.3M vs. $2.3M prior year; prior year included $2.0M SBA loan forgiveness gain.
- Repurchased 10,400 shares in Q3 and 81,303 in first nine months; 1,551,943 shares remain authorized.
- CEO notes revenue growth in U.S. and European consulting markets, citing expansion opportunities.

## SEC filing metadata
- accession: 0001654954-22-012521
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2022-09-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495422012521/0001654954-22-012521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495422012521/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-012521
- JSON: https://secwatch.observer/filing/0001654954-22-012521.json
- Plain text: https://secwatch.observer/filing/0001654954-22-012521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.